• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

American Association for Cancer Research

Novartis headquarters
Pharma

AACR: Novartis makes case for canakinumab in lung cancer

The most important sign from the failed metastatic NSCLC trial that gives Novartis hope in the adjuvant setting lies in a subgroup analysis.
Angus Liu Apr 12, 2022 4:05pm
Box and bottle of Lumakras KRAS cancer drug from Amgen

AACR: Amgen fortifies KRAS lung cancer case with 2-year data

Apr 10, 2022 12:00pm
opdivo

BMS, clinging to Opdivo's lung share, highlights long-term data

Apr 3, 2019 11:09am
Rubraca AstraZeneca

Clovis' Rubraca puts up positive phase 2 pancreatic cancer data

Apr 2, 2019 8:30am
Atlanta

Merck's Keytruda holds its own in tough lung cancer subgroups

Apr 1, 2019 8:30am
Astellas US

Astellas pads Xospata lead with AML survival data

Apr 1, 2019 8:30am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings